The core Antibodies Market Strategy for leading players is a defensive and offensive push centered on innovation and cost-effectiveness:

• Offensive Innovation: The primary strategy is accelerating the development of Next-Generation Antibody formats (Bispecifics, ADCs, Nanobodies) to achieve enhanced therapeutic efficacy through dual targeting and precise payload delivery, minimizing systemic toxicity.

• Defensive IP & Cost Control: A major strategy is managing the impact of patent expiry of successful mAbs (e.g., Humira) by leveraging established global commercialization networks to launch biosimilars or acquire biosimilar portfolios (Mylan/Viatris). Furthermore, companies are investing in advanced manufacturing (e.g., single-use bioreactors) to reduce high production costs and ensure scalability. [Antibodies Market Strategy]